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reviewers independently selected trials, assessed their quality and extracted data. 
Meta-analysis of head-to-head trials was performed. RESULTS: Seven RCTs compar-
ing CIC vs. BUD were identiﬁ ed and included in the analysis. Comparisons of both 
interventions in 1:1 and 1:2 dose ratios were assessed in 3 and 4 trials, respectively. 
CIC as compared with BUD in 1:1 dose ratio was associated with signiﬁ cant improve-
ment in forced vital capacity (FVC) and peak expiratory ﬂ ow (PEF) by spirometry 
(WMD = 0.09 [0.03; 0.14] and WMD = 19.00 [2.37; 35.63], respectively) as well as 
reduction in proportion of symptom-free days (p = 0.018). No statistically signiﬁ cant 
differences between both drugs in 1:2 dose ratios were observed. CIC and BUD in 
either dose showed comparable efﬁ cacy with respect to the risk of asthma exacerba-
tion, improvement in symptoms of asthma and forced expiratory volume in 1 second 
(FEV1). CIC-treated patients experienced less upper respiratory tract infections than 
those treated with BUD in 1:1 dose ratio, however the difference was on the border 
of statistical signiﬁ cance (RR = 0.65 [0.43; 0.99], NNT not signiﬁ cant). There were 
no statistically signiﬁ cant differences between CIC and BUD in either dose ratio with 
respect to risk of adverse events, adverse events related to study medication, pharyn-
gitis and dysphonia. CONCLUSIONS: Ciclesonide provides an improvement in spi-
rometric paramethers and reduction of asthma symptom-free days as compared to 
budesonide in 1:1 dose ratio, while no differences were noticed between CIC and BUD 
in 1:2 dose ratio. Safety proﬁ le of ciclesonide seems to be comparable with budesonide.
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OBJECTIVES: Current asthma management recommendations are based on the level 
of asthma control rather than disease severity. The ﬁ nancial impact associated with 
asthma control needs to be determined. The primary objective of this study was to 
estimate quality of life and health care costs according to the patients’ level of asthma 
control in France and in Spain. METHODS: An observational retrospective bottom-up 
cost of illness study was conducted in adults patients with asthma. Investigators were 
general practitioners. Asthma control was evaluated using the validated auto-test 
Asthma Control Test (ACTTM) for a one month period and 2009 GINA’s asthma 
control criteria for a three months period. Quality of life (QoL) was assessed using 
EQ-5D proﬁ le. Costs (direct and indirect) were evaluated from a societal perspective. 
RESULTS: 794 patients (France: 391; Spain: 403) were enrolled in the ﬁ rst quarterly 
wave of the survey. Based on the ACT, asthma was determined to be well-controlled 
(ACT ≥ 20) in 48.1% [IC 95%: 42.1%–54%] and 56.2% [IC95: 51.1%–61.2%] of 
French and Spanish patients respectively. In both countries, EQ-5D scores were 0.9 
and 0.7 in well-controlled and not well-controlled patients respectively (P < 0.0001). 
Total costs of asthma were directly related to asthma control in both countries. The 
average cost (Euros/month/patient) of well-controlled asthma was c28 (±36) in France 
and c77 (±105) in Spain compared with c140 (±782) (p = 0.0009) and c252 (±380) 
(p < 0.0001) respectively for not well-controlled asthma. Similar associations were 
observed using the latest GINA’s criteria. CONCLUSIONS: We found strong associa-
tions between asthma control level, costs and QoL in patients with asthma. Achieve-
ment of good clinical control of asthma may result in a signiﬁ cant decrease of the 
economic burden of asthma and a better health status in adults.
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OBJECTIVES: The prevalence of asthma has been reported to be increasing for 
decades, but recent studies suggest a leveling off or even decrease in prevalence among 
children. The objective of this study was to assess the trends in anti-asthma medication 
use in Dutch children from 1998 until 2007. METHODS: From the PHARMO Record 
Linkage System, an administrative database network of outpatient pharmacies, hos-
pitals, and other settings, including data of ~4 million individuals in deﬁ ned areas of 
the The Netherlands, we assessed 1) the proportion of children aged 0–19 years with 
at least one dispensing for short (SABA) or long-acting β2-antagonists (LABA), inhaled 
glucocorticoids (ICS), ﬁ xed dose combinations (FDC) of LABA and ICS or leukotriene 
receptor antagonists (LRTA) in the years 1998–2007 stratiﬁ ed by age groups, 2) the 
proportion of users per type for each year and 3) the age distribution per medication 
type for the year 2007. RESULTS: Overall prevalence of anti-asthma medication use 
was approximately 7% and remained stable between 1998 and 2007. Prevalence was 
highest among children aged 0–1 years and declined with increasing age. Over time, 
the prevalence remained stable in all age groups, except for the youngest in which it 
increased from 10% in 1998 to 19% in 2007. Use of ICS and LABA declined over 
time (user proportions: −17% and −3%), against increased use of LABA-ICS FDC and 
LRTA (+15% and +3%). Children <6 years made up relatively large proportions of 
SABA and ICS users, while the older children were more dominant in the other medica-
tion types. CONCLUSIONS: This study provides a comprehensive overview of trends 
in anti-asthma medication use in children showing no overall change in prevalence 
over time. However, a change in type of medication was observed. 
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OBJECTIVES: To compare the impact of different pharmacotherapies on the cost of 
exacerbation of COPD in public hospitals in Hong Kong. METHODS: This was a 
retrospective study comparing the cost of management of chronic obstructive pulmo-
nary disease (COPD) in patients from a public hospital perspective in Hong Kong. 
Institutional ethics approval was obtained. The patients were above 65 years with a 
diagnosis of COPD of stage 3 or above based on the GOLD guideline. COPD was 
deﬁ ned based on ICD-9-CM codes. Two cohorts of patients were included: 1) Those 
who received ﬂ uticasone propionate and salmeterol, plus ipratropium bromide and 
salbutamol inhalation, and 2) Those who received ipratropium bromide and salbuta-
mol, and beclomethasone inhalation. Patients were followed for 6 months before and 
after medications. The date one of the therapies started was the index date. RESULTS: 
A total of 75 patients were recruited over January to June 2008. All values are 
expressed as mean ± SD. The number of emergency room visits and cost of visits 
before and after the index date for both cohorts did not show a signiﬁ cant difference 
(1.86 ± 2.5 days vs. 1.62 ± 1.93 days and HKD1061 ± 1442 vs. HKD924 ± 1102 for 
cohort 1, 1.15 ± 1.28 days vs. 1.02 ± 1.29 days and HKD657 ± 730 vs. HKD582 ± 
735 for cohort 2, p > 0.1). There was a trend of reduction in hospitalization days and 
cost of stay before and after the index date for cohort 1 (although not reaching a 
signiﬁ cant level) but not in cohort 2 (20.6 ± 28.4 days vs. 15.6 ± 18.8 days and 
HKD68162 ± 93875 vs. HKD51662 ± 66278 for cohort 1, 11.1 ± 13.5 days vs. 10.2 
± 13.2 days and HKD36730 ± 44604 vs. HKD33860 ± 43571 for cohort 2, p > 0.1). 
CONCLUSIONS: A trend of reduction in hospital stay was demonstrated (although 
not statistically signiﬁ cant) in patients after receiving combination therapy of ﬂ utica-
sone propionate and salmeterol plus ipratropium bromide and salbutamol. This is 
consistent with earlier studies in other countries. a larger number of patients is 
required to prove the signiﬁ cance of this ﬁ nding.
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OBJECTIVES: To analyze the GP’s prescriptions of bronchodilators for managing the 
patients with stable COPD, to compare the prescriptions with Ukrainian National 
COPD Management Guidelines. And we estimated the annual costs for bronchodila-
tors were used most frequently. METHODS: The analysis of prescription habits based 
on data from outpatient personal medical cards of 103 patients with COPD (2nd 
Municipal Clinic, Bila Tserkva, Ukraine), focused on bronchodilators as central medi-
cations for symptomatic treatment. Among 103 patients 15 were with mild COPD, 
75 with moderate and 13 with severe (according to GOLD). The prescriptions for 
regular treatment were compared with national guidelines. Annual medications costs 
were calculated based on the number of medicines units for 24 hour bronchodilation 
during a year, multiplied by the one unit price in UAH (1 EUR = 10.05 UAH). 
RESULTS: Regular basis was prescribed to 87 patients. Among 87 prescriptions 
13.7% were long-acting inhaled bronchodilators or combinations, 86.3% were short-
acting inhaled bronchodilators, methylexanthines or combinations. Ranking to a 
number of medicines were most frequently prescribed: 56.8% ﬁ xed combination 
Ipratropium/Fenoterol, 10.2% Tiotropium, 9.1% Fenoterol, 7.9% Salbutamol. 
Annual costs for these bronchodilators were: 1206.0, 6262.0, 1303.0 and 275.0 UAH, 
respectively. CONCLUSIONS: The most frequently prescribed bronchodilator was 
Ipratropium/Fenoterol. It’s available during decades and inexpensively. But its basis 
requires triple daily medication, in consequence of that persistency rate might be 
reduced with effectiveness reducing, respectively. Tiotropium ranked second in the 
prescription frequency. It has duration of action of more than 24 hours, high effective-
ness and safety levels but gets 6262.0 UAH annually. So the affordability of a bron-
chodilator is weighty criterion for Ukrainian GP’s prescriptions. But medications costs 
must be scrupulously compared with effectiveness for their including to the national 
formulary and reimbursement decision-making.
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OBJECTIVES: The aim of this study is to analyze the economic impact of non-
adherence to GOLD guidelines in COPD patients. METHODS: A retrospective analy-
sis was carried out in a claim database. Patients ≥40 years-old with diagnosis of COPD 
conﬁ rmed with spirometry (FEV1/FVC < 0.7) were eligible for this analysis. Patients 
were classiﬁ ed into two groups according to whether they fulﬁ ll with therapeutics 
recommendations by severity deﬁ ned in GOLD guidelines (GOLD group) or those 
who don’t fulﬁ ll (NO-GOLD group). Demographics, medical and use of resources 
data were collected and direct and indirect costs were analyzed. a probabilistic mul-
